A pioneering approach to cancer immunotherapy developed by Israeli researchers could vastly improve its effectiveness and expand treatment possibilities to patients for whom conventional therapies have failed.
Researchers at the Weizmann Institute of Science in Rehovot developed a technique that significantly boosts the proliferation of T-cells — key players in the immune system’s defense — while maintaining, and in some cases even enhancing, their ability to kill cancer cells. This advancement addresses a major limitation of current cancer immunotherapies, where T-cells, despite multiplying in large numbers, often lose their cancer-fighting edge.
Cellular immunotherapy, one of the most promising treatments for cancer, recruits the body’s T-cells to target and destroy cancer cells. In this process, T-cells are extracted from the patient, activated, multiplied, and reintroduced into the body to wage war on the cancer. Although this method has shown great potential, its success has been hindered by the fact that after rapid multiplication, T-cells tend to exhaust themselves, losing their potency.
Led by Prof. Benny Geiger from the Weizmann Institute’s Immunology and Regenerative Biology Department, a team of researchers developed what they described as a “synthetic immune niche” — an artificial molecular environment that enhances the performance of T-cells. This niche enables T-cells to reproduce more rapidly without diminishing their cancer-killing abilities.
